Frontal Sinus Malignancies

Bhojwani, Amit; Unsal, Aykut A.; Dubal, Pariket M.; Echanique, Kristen A; Baredes, Soly; Liu, James K.; Eloy, Jean Anderson

doi:10.1177/0194599815621878

Cited by 19 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to the rarity of SCC arising from the frontal sinus, [ 119 ] principles of reconstruction of frontal bone defects resulting from oncologic ablations are less univocally defined. Cranioplasty through titanium, ceramic, or plastic implants is among the most frequently employed strategies, and most invariably requires a two-stage surgery [ 120 ].…”

Section: Treatmentmentioning

confidence: 99%

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Ferrari

Taboni

Carobbio

et al. 2021

Cancers

View full text Add to dashboard Cite

Sinonasal squamous cell carcinoma is a rare tumor affecting the nasal cavity and paranasal sinuses. Several aspects of this disease, ranging from epidemiology to biology, pathology, diagnosis, staging, treatment, and post-treatment surveillance are controversial, and consensus on how to manage this sinonasal cancer is lacking. A narrative literature review was performed to summarize the current evidence and provide the reader with available data supporting the decision-making process in patients affected by sinonasal squamous cell carcinoma, alongside the authors’ personal opinion on the unsolved issues of this tumor. The review has highlighted several advances in molecular definition of epithelial cancers of the sinonasal tract. Surgery represents the pivot of treatment and is performed through an endoscopic transnasal approach whenever feasible. Open surgery is required for a large proportion of cases. Reconstruction of the defect follows principles of skull base and cranio-maxillo-facial reconstruction. Chemotherapy is given as neoadjuvant treatment or concomitantly to radiotherapy. Photon-based radiation therapy has a crucial role in the adjuvant setting. Particle therapy is providing promising results. Management of the neck should be planned based on the presence of clinically appreciable metastases, primary tumor extension, and need for recipient vessels. Biotherapy and immunotherapy are still underexplored therapeutical modalities.

show abstract

Section: Treatmentmentioning

confidence: 99%

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Ferrari

Taboni

Carobbio

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Bhojwani et al. reported that the incidence of frontal sinus malignancies in their study was 0.011 per 100,000 individuals during a 12-year period, with squamous cell carcinoma as the most common histologic etiology, followed by NHL [10] .…”

Section: Discussionmentioning

confidence: 85%

Primary diffuse large B-cell lymphoma of the frontal sinus: A case report and literature review

Nagafuji

Yokoi

Ohara

et al. 2018

Radiology Case Reports

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma arising as a primary tumor in the frontal sinus is very rare. Moreover, it is often difficult to diagnose frontal sinus lesions. A 67-year-old Japanese man initially presented with diplopia and a swollen left upper eyelid. Diffusion-weighted magnetic resonance imaging suggested a malignant lymphoma of the frontal sinus, and subsequent extensive examination revealed diffuse large B-cell lymphoma of the frontal sinus with left orbital invasion. Six courses of combined immunodirected chemotherapy were administered. The patient is tumor-free owing to the accurate diagnosis of lymphoma at an early stage.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Malignancies primarily originating from the frontal sinus (FS) are rarely described in the literature 1–4 . Histologically, squamous cell carcinomas (SCC) make up the majority of malignant paranasal sinus tumours in humans 2–5 . Other diagnoses include non‐Hodgkin B‐cell lymphomas, carcinomas‐non‐otherwise‐specified (CA‐NOS) and adenocarcinomas 2–4 …”

Section: Introductionmentioning

confidence: 99%

“…Besides (neo‐)adjuvant chemotherapy, molecular targeted therapy strategies, such as kinase‐inhibitors and monoclonal antibodies targeting epidermal growth factor receptor (EGFR) are currently being investigated in humans in addition to local treatment 18–21 . Nevertheless, prognosis remains poor with five‐year survival rates for FSC ranging from 15.4% to 36.4% 3,21,22 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Frontal sinus carcinoma in forty‐one dogs (2001–2022)

Gedon¹,

Kessler²,

Schmidt³

2023

Vet Comparative Oncology

View full text Add to dashboard Cite

Reports on canine frontal sinus carcinomas (FSCs) are scarce. This retrospective review of 41 dogs with FSC (2001–2022) describes demographic and clinical characteristics of canine FSC and reports the clinical experience and overall survival following treatment with toceranib phosphate (TOC) and meloxicam in 10 cases. Median age at diagnosis was 10.6 years (range: 6.5–15.4 years). There was a male‐to‐female‐ratio of 2.4:1. The most common breeds were Jack Russell Terriers (JRT) (n = 7; 17.1%) and Rottweilers (n = 3, 7.3%). Mesocephalic breeds (70.6%) were most commonly affected, brachycephalics accounted for 8.8%. The most frequent clinical signs included skull deformation dorsomedial to the eye (87.5%), pain/head‐shyness (40.0%), ocular (22.5%)/nasal (17.5%) discharge, and exophthalmos (17.5%). Duration of symptoms prior to diagnosis varied from a few days to 9 months. There were no neurological signs at initial presentation despite imaging evidence of osteolysis of the lamina interna of the frontal bone in most dogs (69.4%). In 11.5%, pulmonary changes suggestive of metastasis or concurrent primary pulmonary neoplasia were present. Tumour types included squamous cell carcinoma (58.5%), unspecified carcinoma (29.3%), and adenocarcinoma (9.8%). Ten dogs were treated with TOC (median 2.8 mg/kg EOD or three times per week) and meloxicam (0.1 mg/kg, EOD) (TOC‐M), resulting in subjective regression of skull deformity in 8/10 (80.0%) patients. Overall median survival time with TOC‐M was 183.5 days (range: 120–434 days). FSCs typically present with skull deformation, but no overt neurological signs. Male dogs and JRT may be overrepresented. The use of TOC‐M in FSC appears promising and warrants further prospective evaluation.

show abstract

Frontal Sinus Malignancies

Abstract: Malignant tumors of the frontal sinus are rare and are more common in males. Squamous cell carcinoma is the most common entity encountered. Of the 4 most common histologies, survival is best for mature B-cell non-Hodgkin's lymphomas and worst for adenocarcinomas.

Cited by 19 publications

References 27 publications

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence

Primary diffuse large B-cell lymphoma of the frontal sinus: A case report and literature review

Frontal sinus carcinoma in forty‐one dogs (2001–2022)

Contact Info

Product

Resources

About